New Outpatient Screening Tool Pinpoints Problems During Cancer Treatment

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 6
Volume 11
Issue 6

BALTIMORE-Medical personnel are often "dreadful" at singling out individuals facing mood disturbances, emotional issues, and practical problems that can cause severe distress during cancer treatment, according to Matthew Loscalzo, MSW, director of patient and family services and co-director of oncology pain services at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore. A new screening and assessment tool used at the onset of treatment, however, identifies the issues most important to each individual patient and allows staff to promptly arrange for needed services, he told an industry-sponsored symposium held in conjunction with the Oncology Nursing Society annual meeting.

BALTIMORE—Medical personnel are often "dreadful" at singling out individuals facing mood disturbances, emotional issues, and practical problems that can cause severe distress during cancer treatment, according to Matthew Loscalzo, MSW, director of patient and family services and co-director of oncology pain services at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore. A new screening and assessment tool used at the onset of treatment, however, identifies the issues most important to each individual patient and allows staff to promptly arrange for needed services, he told an industry-sponsored symposium held in conjunction with the Oncology Nursing Society annual meeting.

Developed at Hopkins, the pencil-and-paper checklist covers physical and psychological symptoms as well as issues involving the patient’s responsibilities and activities. It also forms the basis for the National Comprehensive Cancer Network Distress Panel’s recommendations, Mr. Loscalzo said.

Patients using the instrument generally cite between 8 and 13 serious problems, with fatigue, pain, and transportation topping the list. Other common complaints include worry, anorexia, insomnia, and irritability, he reported. Having specific information about the needs of individual patients greatly aids nurses in helping patients manage their quality of life and treatment plans, he added.

Obstacles to Reporting

Many obstacles prevent patients from volunteering information symptoms and resource deficits that can affect not only their treatment but their entire quality of life, Mr. Loscalzo continued. Prominent among these obstacles are the desire to be a "good patient" and the belief that such issues are "too trivial" to bring to professionals’ attention, he said. Low energy, which affects between 40% and 80% of patients, also plays a role.

Because lack of energy is a symptom of both treatment-related fatigue and depression, discerning its origin is vital to providing high-quality care to the "whole person," Mr. Loscalzo said. The screening tool has proven very useful in this regard, he added. By doing universal and systematic screening and assessment of patients’ and families’ needs—facilitated by the screening tool—oncology nurses are "going to do the same thing with fatigue as [they] did with pain," Mr. Loscalzo concluded.

Recent Videos
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Two experts are featured in this series.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
Related Content